 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a693021 |
| Routes of administration | Intravenous,intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 29% |
| Eliminationhalf-life | 0.65–1.20 hrs |
| Excretion | Mainly kidneys (41–66% within 8 hrs) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.063.506 |
| Chemical and physical data | |
| Formula | C8H11NO5S |
| Molar mass | 233.24 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 148 to 151 °C (298 to 304 °F) |
| |
| |
| (verify) | |
Sulbactam is aβ-lactamase inhibitor. Thisdrug is given in combination withβ-lactam antibiotics to inhibitβ-lactamase, anenzyme produced bybacteria that destroys theantibiotics.[1]
It was patented in 1977 and approved for medical use in 1986.[2]
The combinationampicillin/sulbactam (Unasyn) is available in the United States.[3]
The combinationcefoperazone/sulbactam (Sulperazon) is available in many countries but not in the United States.[4]
The co-packaged combinationsulbactam/durlobactam was approved for medical use in the United States in May 2023.[5]
Sulbactam is primarily used as asuicide inhibitor of β-lactamase, shielding more potent beta-lactams such as ampicillin.[6] Sulbactam itself contains abeta-lactam ring, and has weak antibacterial activity by inhibitingpenicillin binding proteins (PBP) 1 and 3, but not 2.[7]
